Unither Therapeutics

Unither Therapeutics is a biotechnology subsidiary of United Therapeutics Corporation focused on developing broad-spectrum antiviral therapies. The company utilizes a glycobiology platform to create iminosugar-based small molecules that inhibit host alpha-glucosidase enzymes. By targeting the host's protein-folding machinery rather than the virus itself, these therapies aim to prevent the maturation of viral glycoproteins across multiple viral families. Key programs include UV-4B, which has been investigated for the treatment of Dengue fever and other infectious diseases. The company's approach is designed to provide a high barrier to viral resistance, making it a strategic asset in pandemic preparedness and global health.